Unknown

Dataset Information

0

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy.

ABSTRACT:

SUBMITTER: Rhoades R 

PROVIDER: S-EPMC8053597 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO.
| S-EPMC6971875 | biostudies-literature
Unknown Monitoring of COVID-19-Associated Coagulopathy and Anticoagulation with Thromboelastometry.
| S-EPMC8018202 | biostudies-literature
Unknown Favorable Outcomes of Anticoagulation With Unfractioned Heparin in Sepsis-Induced Coagulopathy: A Retrospective Analysis of MIMIC-III Database.
| S-EPMC8761617 | biostudies-literature
Unknown Self-monitoring and self-management of oral anticoagulation.
| S-EPMC8078378 | biostudies-literature
Unknown Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.
| S-EPMC7839371 | biostudies-literature
Unknown Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
| S-EPMC7537066 | biostudies-literature
Unknown Anticoagulation management.
| S-EPMC3324206 | biostudies-other
Unknown Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study.
| S-EPMC8019180 | biostudies-literature
Unknown Ixolaris: a factor Xa heparin-binding exosite inhibitor.
| S-EPMC1135020 | biostudies-other
Unknown Zn(2+)-heparin interaction studied by potentiometric titration.
| S-EPMC1133085 | biostudies-other